替米沙坦对高血压前期患者高敏C反应蛋白的影响  

作　　者：吕雅萍[1] 张爱华[1] 张杰[1] 

机构地区：[1]沧州市中心医院大化分院内科,河北沧州市061000

出　　处：《现代妇女（医学前沿）》2014年第8期8-8,共1页Modern Women

摘　　要：目的分析替米沙坦对高血压前期患者高敏c反应蛋白的影响。方法选取我FG2011年1月-2013年1月期间收治的98例高血压前期患者，随机分为A、B两组，给予A组患者硝苯地平控释片治疗，给予B组患者替米沙坦治疗，对两组患者·临床治疗效果进行对比。结果A、B两组患者组内对比，治疗后收缩压、舒张压均比之治疗前有明显改善，差异显著具有统计学意义（P〈0．05）；A、B两组组间对比，差异图统计学意义（p〉0．05）。结论替米沙坦可有效降低高血压前期患者高敏C反应蛋白，提高临床治疗效果，值得临床推广与应用。objective to analyze telmisartan high-sensitivity c-reactive protein in patients with prehypertension. Methods select our hospital from January 2011 to January 2011 admitted during the period of 98 patients with prehypertension, were randomly divided into A, B two groups, group A patients＇ nifedipine retard-20 tablet treatment, give telmisartan treatment group B patients, clinical therapeutic effect of two groups of patients were compared. Results within the group A, B two groups of patients, the systolic pressure, diastolic blood pressure after treatment were obviously improved than before treatment, significant difference statistically significant （P 〈 0.05）; Contrast, the difference between A and B two way figure statistical significance （P 〉 0.05）. Conclusion telmisartan can effectively reduce the early high-sensitivity c-reactive protein in patients with high blood pressure, improve the effect of clinical treatment, worthy of clinical popularization and application.

关 键 词：替米沙坦 高血压前期 高敏C反应蛋白 

分 类 号：R544.1[医药卫生—心血管疾病]